The following are the active clinical trials currently available or anticipated in the Center for Adoptive Cellular Therapy.

Open CAR T-cell Clinical Trials

AALL1721 (CASSIOPEIA): A Phase 2 Trial of tisagenlecleucel in first-line high-risk pediatric and young adult patients with B-ALL who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy. This trial is sponsored by Novartis.

• ClinicalTrials.gov Identifier: NCT03876769. Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients - Full Text View - ClinicalTrials.gov 

Upcoming CAR T-cell Clinical Trials

JCAR017 BCM004: A Phase 1/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL. This trial is sponsored by Bristol-Myers Squibb

• ClinicalTrials.gov Identifier: NCT03743246. A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) - Full Text View - ClinicalTrials.gov